Compounded GLP-1s Why doctors worry and FDA acts
Compounded GLP-1s Why doctors worry and regulators are acting is no longer a shortage-era side story. After FDA declared tirzepatide and semaglutide injection shortages resolved, the agency moved in 2026 to curb mass-marketed compounded copies, warn telehealth marketers, and keep key active ingredients off the outsourcing-facility bulks list.
Contents10 sections
Key Takeaways
- Compounded GLP-1 products are not FDA-approved; FDA does not pre-review their safety, effectiveness, or quality.
- FDA said in February 2026 it intends to restrict GLP-1 APIs used in non-approved compounded drugs that are mass-marketed as alternatives to approved medicines.
- In March 2026, FDA issued 30 warning letters to telehealth firms for false or misleading compounded GLP-1 marketing claims.
- In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk.
Compounded GLP-1s at a glance
| Field | Detail |
|---|---|
| Products in focus | Compounded semaglutide, tirzepatide, and related GLP-1 injectable products |
| Approved reference drugs | FDA-approved GLP-1 products (e.g., branded semaglutide and tirzepatide injectables) |
| Shortage status | FDA determined tirzepatide and semaglutide injection shortages resolved (2024–2025 updates) |
| Key 2026 actions | Feb intent-to-restrict statement; March telehealth warning letters; April 503B bulks-list proposal |
| Legal framework | FD&C Act sections 503A (state-licensed pharmacies/physicians) and 503B (outsourcing facilities) |
| Core FDA concern | Unverified quality/safety/efficacy and marketing that implies sameness with approved drugs |
Why do doctors and FDA worry about compounded GLP-1s?
Compounded drugs can fill real gaps — a patient-specific need or a true shortage. They are not a shadow generics channel. In its March 2026 warning-letter announcement, FDA stressed that compounded drugs are not FDA-approved and are not the same as generic drugs, which do go through FDA approval.
That distinction drives clinical worry. Prescribers cannot assume a compounded semaglutide or tirzepatide product matches the approved drug's purity, potency, sterility, or dose delivery. Patients who saw compounded versions marketed as "the same active ingredient" as Wegovy, Ozempic, Mounjaro, or Zepbound may think they are getting an equivalent product. FDA says they are not.
What changed after the shortages ended?
During shortages, compounding under sections 503A and 503B had a wider practical runway. FDA later determined the tirzepatide injection shortage was resolved and, in February 2025, that the semaglutide injection shortage was also resolved. FDA's compounding policy update as GLP-1 supply stabilized walks through the wind-down of enforcement discretion and the copy restrictions that return when commercial supply is available.
As of FDA's April 2026 reminder on that page, tirzepatide and semaglutide do not appear on the 503B bulks list or on FDA's drug shortage list. That combination sharply limits lawful bulk compounding of those APIs by outsourcing facilities, and it tightens 503A "essentially a copy" limits for state-licensed pharmacies.
What did FDA announce in February and March 2026?
On 6 February 2026, FDA said it intends to take decisive steps to restrict GLP-1 APIs intended for use in non-FDA-approved compounded drugs that companies mass-market as similar alternatives to approved products. FDA's February 2026 statement on non-approved GLP-1 drugs also flagged misleading advertising — including claims that compounded products are generics, use the "same" active ingredient in a way that implies equivalence, or are clinically proven like approved drugs.
On 3 March 2026, FDA announced 30 warning letters to telehealth companies for false or misleading compounded GLP-1 claims. FDA's March telehealth warning-letter announcement cited claims implying sameness with FDA-approved products and branding that obscured who actually compounded the drug.
What is the April 2026 503B bulks-list proposal?
On 30 April 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. FDA's 503B bulks-list proposal for GLP-1 APIs said the agency found no clinical need for outsourcing facilities to compound those substances from bulk when FDA-approved drugs are available.
Under 503B, outsourcing facilities generally cannot compound from bulk unless the substance is on the bulks list or the finished drug is on the shortage list at compounding, distribution, and dispensing. A final exclusion would close the main bulk pathway for large-scale compounded copies of these GLP-1s.
What still remains allowed?
FDA still describes compounding as important for shortages and unique patient needs. The April 1, 2026 policy reminder explains that a 503A compound may avoid the "essentially a copy" bar when a prescriber documents a significant difference for an identified patient. It also notes a narrow enforcement posture for very small copy volumes (four or fewer prescriptions of that compounded product in a calendar month).
Those are narrow lanes, not a green light for telehealth menus of compounded "semaglutide" or "tirzepatide" sold as routine substitutes. Mass marketing that implies FDA approval or clinical proof remains a misbranding risk.
Related NovaPharma coverage
- Chile food warning labels and obesity-risk evidence
- FDA Salmonella moringa leaf powder recall
- FDA human-factors guidance for marketing submissions
Frequently Asked Questions
Are compounded GLP-1 drugs FDA-approved?
No. The FDA states that compounded drugs are not FDA-approved and that the agency does not review their safety, effectiveness, or quality before they are marketed. Compounded products are also not the same as FDA-approved generic drugs.
What enforcement steps has FDA taken on compounded GLP-1s in 2026?
In February 2026, FDA said it intends to restrict GLP-1 active ingredients used in non-FDA-approved compounded drugs that are mass-marketed as alternatives to approved products. In March 2026, it issued 30 warning letters to telehealth companies for false or misleading compounded GLP-1 claims. In April 2026, it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
Can compounders still make copies of Wegovy, Ozempic, or Zepbound?
Generally no, once the approved products are commercially available and not on FDA's shortage list. FDA has said tirzepatide and semaglutide injection shortages are resolved and that those APIs do not appear on the 503B bulks list. Sections 503A and 503B limit compounding drugs that are essentially copies of commercially available or FDA-approved products, with narrow patient-specific exceptions.
Primary Sources
- FDA: Intends to take action against non-FDA-approved GLP-1 drugs (6 Feb 2026)
- FDA: Warns 30 telehealth companies over compounded GLP-1 marketing (3 Mar 2026)
- FDA: Clarifies compounding policies as GLP-1 supply stabilizes
- FDA: Proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list (30 Apr 2026)
This article follows our editorial standards. Report a correction via editorial contact.
